Positron emission tomography and stereotactic body radiation therapy for lung cancer: From treatment planning to response evaluation

Positron emission tomography and stereotactic body radiation therapy for lung cancer: From treatment planning to response evaluation

Stereotactic body radiation therapy is the standard treatment for inoperable patients with early-stage lung cancer. Local control rates range from 80 to 90 % 2 years after treatment. The role of positron emission tomography in patient selection is well known, but its use for target definition or the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer radiothérapie 2015-12, Vol.19 (8), p.790-4; quiz 795-9
Hauptverfasser: Bibault, J-E, Oudoux, A, Durand-Labrunie, J, Mirabel, X, Lartigau, É, Kolesnikov-Gauthier, H
Format: Artikel
Sprache:fre
Schlagworte:
Fluorodeoxyglucose F18
Humans
Lung Neoplasms - diagnostic imaging
Lung Neoplasms - surgery
Patient Care Planning
Positron-Emission Tomography
Radiopharmaceuticals
Radiosurgery
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4; quiz 795-9
container_issue 8
container_start_page 790
container_title Cancer radiothérapie
container_volume 19
creator Bibault, J-E
Oudoux, A
Durand-Labrunie, J
Mirabel, X
Lartigau, É
Kolesnikov-Gauthier, H
description Stereotactic body radiation therapy is the standard treatment for inoperable patients with early-stage lung cancer. Local control rates range from 80 to 90 % 2 years after treatment. The role of positron emission tomography in patient selection is well known, but its use for target definition or therapeutic response evaluation is less clear. We reviewed the literature in order to assess the current state of knowledge in this area.
doi_str_mv 10.1016/j.canrad.2015.05.027
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1750003031</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1750003031</sourcerecordid><originalsourceid>FETCH-LOGICAL-p141t-54446dfa83fb719e600edc6a9546dcf7bb41f42f302aa4d871edba8b24a155133</originalsourceid><addsrcrecordid>eNo1kMFKxDAQhoMg7rr6BiI5emlN2jRpvcniqrCgBz2XaTPd7dI2NUmF3n1ww7rCwAwzH__8M4TccBZzxuX9Ia5hsKDjhPEsZiESdUaWXMkikjLLF-TSuQNjTMoiuyCLRAolFUuW5OfduNZbM1DsW-faUHjTm52FcT9TGDR1Hi0aD7Vva1oZPdOwqAV_RPcYwJk2xtJuGnY02KjRPtCNNT31FsH3OHg6djAMbZh7Qy260QwOKX5DNx11rsh5A53D61Nekc_N08f6Jdq-Pb-uH7fRyAX3USaEkLqBPG0qxQuUjKGuJRRZaNeNqirBG5E0KUsAhM4VR11BXiUCeJbxNF2Ruz_d0ZqvCZ0vw801dsEdmsmVXGXhRylLeUBvT-hU9ajL0bY92Ln8_1z6C0XedAY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1750003031</pqid></control><display><type>article</type><title>Positron emission tomography and stereotactic body radiation therapy for lung cancer: From treatment planning to response evaluation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Bibault, J-E ; Oudoux, A ; Durand-Labrunie, J ; Mirabel, X ; Lartigau, É ; Kolesnikov-Gauthier, H</creator><creatorcontrib>Bibault, J-E ; Oudoux, A ; Durand-Labrunie, J ; Mirabel, X ; Lartigau, É ; Kolesnikov-Gauthier, H</creatorcontrib><description>Stereotactic body radiation therapy is the standard treatment for inoperable patients with early-stage lung cancer. Local control rates range from 80 to 90 % 2 years after treatment. The role of positron emission tomography in patient selection is well known, but its use for target definition or therapeutic response evaluation is less clear. We reviewed the literature in order to assess the current state of knowledge in this area.</description><identifier>EISSN: 1769-6658</identifier><identifier>DOI: 10.1016/j.canrad.2015.05.027</identifier><identifier>PMID: 26476702</identifier><language>fre</language><publisher>France</publisher><subject>Fluorodeoxyglucose F18 ; Humans ; Lung Neoplasms - diagnostic imaging ; Lung Neoplasms - surgery ; Patient Care Planning ; Positron-Emission Tomography ; Radiopharmaceuticals ; Radiosurgery</subject><ispartof>Cancer radiothérapie, 2015-12, Vol.19 (8), p.790-4; quiz 795-9</ispartof><rights>Copyright © 2015 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26476702$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bibault, J-E</creatorcontrib><creatorcontrib>Oudoux, A</creatorcontrib><creatorcontrib>Durand-Labrunie, J</creatorcontrib><creatorcontrib>Mirabel, X</creatorcontrib><creatorcontrib>Lartigau, É</creatorcontrib><creatorcontrib>Kolesnikov-Gauthier, H</creatorcontrib><title>Positron emission tomography and stereotactic body radiation therapy for lung cancer: From treatment planning to response evaluation</title><title>Cancer radiothérapie</title><addtitle>Cancer Radiother</addtitle><description>Stereotactic body radiation therapy is the standard treatment for inoperable patients with early-stage lung cancer. Local control rates range from 80 to 90 % 2 years after treatment. The role of positron emission tomography in patient selection is well known, but its use for target definition or therapeutic response evaluation is less clear. We reviewed the literature in order to assess the current state of knowledge in this area.</description><subject>Fluorodeoxyglucose F18</subject><subject>Humans</subject><subject>Lung Neoplasms - diagnostic imaging</subject><subject>Lung Neoplasms - surgery</subject><subject>Patient Care Planning</subject><subject>Positron-Emission Tomography</subject><subject>Radiopharmaceuticals</subject><subject>Radiosurgery</subject><issn>1769-6658</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMFKxDAQhoMg7rr6BiI5emlN2jRpvcniqrCgBz2XaTPd7dI2NUmF3n1ww7rCwAwzH__8M4TccBZzxuX9Ia5hsKDjhPEsZiESdUaWXMkikjLLF-TSuQNjTMoiuyCLRAolFUuW5OfduNZbM1DsW-faUHjTm52FcT9TGDR1Hi0aD7Vva1oZPdOwqAV_RPcYwJk2xtJuGnY02KjRPtCNNT31FsH3OHg6djAMbZh7Qy260QwOKX5DNx11rsh5A53D61Nekc_N08f6Jdq-Pb-uH7fRyAX3USaEkLqBPG0qxQuUjKGuJRRZaNeNqirBG5E0KUsAhM4VR11BXiUCeJbxNF2Ruz_d0ZqvCZ0vw801dsEdmsmVXGXhRylLeUBvT-hU9ajL0bY92Ln8_1z6C0XedAY</recordid><startdate>201512</startdate><enddate>201512</enddate><creator>Bibault, J-E</creator><creator>Oudoux, A</creator><creator>Durand-Labrunie, J</creator><creator>Mirabel, X</creator><creator>Lartigau, É</creator><creator>Kolesnikov-Gauthier, H</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201512</creationdate><title>Positron emission tomography and stereotactic body radiation therapy for lung cancer: From treatment planning to response evaluation</title><author>Bibault, J-E ; Oudoux, A ; Durand-Labrunie, J ; Mirabel, X ; Lartigau, É ; Kolesnikov-Gauthier, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p141t-54446dfa83fb719e600edc6a9546dcf7bb41f42f302aa4d871edba8b24a155133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2015</creationdate><topic>Fluorodeoxyglucose F18</topic><topic>Humans</topic><topic>Lung Neoplasms - diagnostic imaging</topic><topic>Lung Neoplasms - surgery</topic><topic>Patient Care Planning</topic><topic>Positron-Emission Tomography</topic><topic>Radiopharmaceuticals</topic><topic>Radiosurgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bibault, J-E</creatorcontrib><creatorcontrib>Oudoux, A</creatorcontrib><creatorcontrib>Durand-Labrunie, J</creatorcontrib><creatorcontrib>Mirabel, X</creatorcontrib><creatorcontrib>Lartigau, É</creatorcontrib><creatorcontrib>Kolesnikov-Gauthier, H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer radiothérapie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bibault, J-E</au><au>Oudoux, A</au><au>Durand-Labrunie, J</au><au>Mirabel, X</au><au>Lartigau, É</au><au>Kolesnikov-Gauthier, H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Positron emission tomography and stereotactic body radiation therapy for lung cancer: From treatment planning to response evaluation</atitle><jtitle>Cancer radiothérapie</jtitle><addtitle>Cancer Radiother</addtitle><date>2015-12</date><risdate>2015</risdate><volume>19</volume><issue>8</issue><spage>790</spage><epage>4; quiz 795-9</epage><pages>790-4; quiz 795-9</pages><eissn>1769-6658</eissn><abstract>Stereotactic body radiation therapy is the standard treatment for inoperable patients with early-stage lung cancer. Local control rates range from 80 to 90 % 2 years after treatment. The role of positron emission tomography in patient selection is well known, but its use for target definition or therapeutic response evaluation is less clear. We reviewed the literature in order to assess the current state of knowledge in this area.</abstract><cop>France</cop><pmid>26476702</pmid><doi>10.1016/j.canrad.2015.05.027</doi></addata></record>
fulltext fulltext
identifier EISSN: 1769-6658
ispartof Cancer radiothérapie, 2015-12, Vol.19 (8), p.790-4; quiz 795-9
issn 1769-6658
language fre
recordid cdi_proquest_miscellaneous_1750003031
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Fluorodeoxyglucose F18
Humans
Lung Neoplasms - diagnostic imaging
Lung Neoplasms - surgery
Patient Care Planning
Positron-Emission Tomography
Radiopharmaceuticals
Radiosurgery
title Positron emission tomography and stereotactic body radiation therapy for lung cancer: From treatment planning to response evaluation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T12%3A24%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Positron%20emission%20tomography%20and%20stereotactic%20body%20radiation%20therapy%20for%20lung%20cancer:%20From%20treatment%20planning%20to%20response%20evaluation&rft.jtitle=Cancer%20radioth%C3%A9rapie&rft.au=Bibault,%20J-E&rft.date=2015-12&rft.volume=19&rft.issue=8&rft.spage=790&rft.epage=4;%20quiz%20795-9&rft.pages=790-4;%20quiz%20795-9&rft.eissn=1769-6658&rft_id=info:doi/10.1016/j.canrad.2015.05.027&rft_dat=%3Cproquest_pubme%3E1750003031%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1750003031&rft_id=info:pmid/26476702&rfr_iscdi=true